ArticleAnnals of laboratory medicine2015
Species-specific difference in antimicrobial susceptibility among viridans group streptococci.
Article in Annals of laboratory medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Choice of antimicrobial therapy for infective endocarditis caused by viridans streptococci: an international practice survey.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Factors Contributing to Delayed Initiation of Appropriate Antimicrobial Treatment in Patients With Streptococcal Bacteremia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Population genomics of Streptococcus mitis in UK and Ireland bloodstream infection and infective endocarditis cases.Nature communications · 2024Article
- Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study.JAC-antimicrobial resistance · 2024Article
- Insights into the role ofFrontiers in cellular and infection microbiology · 2024Review
- The clinical Spectrum of Viridans Group Streptococci infections in paediatric patients at a tertiary hospital.Southern African journal of infectious diseases · 2024Article
- Clinical and microbiological profile of Viridans group streptococcal bacteraemia; experience from South India.Le infezioni in medicina · 2024Article
- Microbiological Epidemiology of Invasive Infections Due to Non-Beta-Hemolytic Streptococci, France, 2021.Microbiology spectrum · 2023Article
- Article
- Pediatric Brain Abscesses, Epidural Empyemas, and Subdural Empyemas Associated with Streptococcus Species - United States, January 2016-August 2022.MMWR. Morbidity and mortality weekly report · 2022Article
- Laboratory Diagnosis, Antimicrobial Susceptibility And Genuine Clinical Spectrum ofMedical archives (Sarajevo, Bosnia and Herzegovina) · 2022Article
- Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020.JAC-antimicrobial resistance · 2022Article
- Multidrug-Resistant Bacteria: Their Mechanism of Action and Prophylaxis.BioMed research international · 2022Review
- Cefazolin versus ampicillin/sulbactam as an empiric antibiosis in severe odontogenic neck infection descending from the lower jaw-retrospective analysis of 350 cases.Clinical oral investigations · 2021Article
- Multiple Deep-seated Dentofacial Abscesses Caused by Multidrug-resistant Viridans Group Streptococci.Internal medicine (Tokyo, Japan) · 2020Article
- Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches.Molecules (Basel, Switzerland) · 2020Review
- Article
- An intubated 7-month-old infant with a retropharyngeal abscess and multidrug-resistantClinical case reports · 2019Article
- Clinical Significance of Isolates Known to Be Blood Culture Contaminants in Pediatric Patients.Medicina (Kaunas, Lithuania) · 2019Article
- A Case of Urinary Sepsis Secondary toCase reports in infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViridans group streptococci (VGS) are both commensal microbes and potential pathogens. Increasing resistance to penicillin in VGS is an ongoing issue in the clinical environment. We investigated the difference in susceptibility and resistance to penicillin among various VGS species.
methodsIn total 1,448 VGS isolated from various clinical specimens were analyzed over a two-yr period. Identification and antimicrobial susceptibility test was performed by the automated VITEK 2 system (bioMerieux, France) or the MicroScan MICroSTREP system (Siemens, Germany).
resultsAmong the 1,448 isolates, 412 were isolated from blood (28.4%). Streptococcus mitis group was the most frequently isolated (589 isolates, 40.7%), followed by the S. anginosus group (290 isolates, 20.0%), S. sanguinis group (179 isolates, 12.4%) and S. salivarius group (57 isolates, 3.9%). In total, 314 isolates could not be identified up to the species level. The overall non-susceptibility to penicillin was observed to be 40.0% (resistant, 11.2% and intermediately resistant, 28.8%) with uneven distribution among groups; 40.2% in S. sanguinis group (resistant, 5.0% and intermediately resistant, 35.2%), 60.3% in S. mitis group (resistant, 20.9% and intermediately resistant, 39.4%), 78.9% in S. salivarius group (resistant, 8.8% and intermediately resistant, 70.1%), and 6.2% in S. anginosus group (resistant, 1.7% and intermediately resistant, 4.5%).
conclusionsAntimicrobial resistance patterns towards penicillin show differences among various VGS; this should be considered while devising an effective antimicrobial treatment against VGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.